Plasma concentrations of caspofungin in a critically ill patient with morbid obesity

Crit Care. 2017 Aug 2;21(1):200. doi: 10.1186/s13054-017-1774-2.

Authors

Rafael Ferriols-Lisart¹, Gerardo Aguilar², Alejandro Pérez-Pitarch³, Jaume Puig², Carlos Ezquer-Garín⁴, Manuel Alós³

Affiliations

¹ Department of Pharmacy, University Clinical Hospital of Valencia, Avda. Blasco Ibañez 17, Valencia, Spain. [email protected].
² Surgical Intensive Care Unit, Department of Anesthesiology and Intensive Care, Hospital Clínico Universitario, Valencia, Spain.
³ Department of Pharmacy, University Clinical Hospital of Valencia, Avda. Blasco Ibañez 17, Valencia, Spain.
⁴ Health Research Institute, INCLIVA, Avenida Blasco Ibáñez 17, 46010, Valencia, Spain.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antifungal Agents / adverse effects
Antifungal Agents / chemistry
Antifungal Agents / therapeutic use
Candidiasis
Caspofungin
Critical Illness / classification*
Critical Illness / epidemiology
Echinocandins / adverse effects
Echinocandins / chemistry*
Echinocandins / therapeutic use
Humans
Intensive Care Units / organization & administration
Lipopeptides / adverse effects
Lipopeptides / chemistry*
Lipopeptides / therapeutic use
Male
Middle Aged
Obesity, Morbid / blood*
Obesity, Morbid / complications
Shock, Septic

Substances

Antifungal Agents
Echinocandins
Lipopeptides
Caspofungin